OncoSec Medical Crescita futura

Future criteri di controllo 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di OncoSec Medical.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Biotechs crescita degli utili	28.5%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Recent updates

OncoSec to cut workforce by 45% as part of corporate restructuring

Oct 04

What Type Of Shareholders Make Up OncoSec Medical Incorporated's (NASDAQ:ONCS) Share Registry?

Jan 28

Dosing underway in OncoSec's Tavo combo trial in skin cancer

Jan 08

OncoSec: Undervalued And Continuing To Make Progress

Nov 18

OncoSec drops 11% despite positive data from TAVO + Merck's Keytruda in metastatic melanoma

Nov 09

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché OncoSec Medical non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

OTCPK:ONCS.Q - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
1/31/2023	N/A	-29	-25	-25	N/A
10/31/2022	N/A	-32	-29	-28	N/A
7/31/2022	N/A	-34	-32	-32	N/A
4/30/2022	N/A	-38	-34	-34	N/A
1/31/2022	N/A	-41	-42	-41	N/A
10/31/2021	N/A	-42	-43	-42	N/A
7/31/2021	N/A	-45	-43	-42	N/A
4/30/2021	N/A	-42	-44	-43	N/A
1/31/2021	N/A	-43	-38	-38	N/A
10/31/2020	N/A	-46	-35	-35	N/A
7/31/2020	N/A	-42	-33	-33	N/A
4/30/2020	N/A	-41	-32	-32	N/A
1/31/2020	N/A	-38	-31	-31	N/A
10/31/2019	N/A	-32	-30	-30	N/A
7/31/2019	N/A	-30	-29	-29	N/A
4/30/2019	N/A	-35	-27	-27	N/A
1/31/2019	N/A	-38	-25	-25	N/A
10/31/2018	N/A	-41	-25	-25	N/A
7/31/2018	N/A	-39	-23	-23	N/A
4/30/2018	N/A	-33	-22	-22	N/A
1/31/2018	N/A	-27	-20	-20	N/A
10/31/2017	N/A	-22	-18	-18	N/A
7/31/2017	N/A	-21	-17	-17	N/A
4/30/2017	N/A	-22	-17	-17	N/A
1/31/2017	N/A	-24	-18	-17	N/A
10/31/2016	N/A	-25	N/A	-18	N/A
7/31/2016	N/A	-27	N/A	-18	N/A
4/30/2016	N/A	-27	N/A	-19	N/A
1/31/2016	N/A	-27	N/A	-19	N/A
10/31/2015	N/A	-24	N/A	-19	N/A
7/31/2015	N/A	-21	N/A	-18	N/A
4/30/2015	N/A	-18	N/A	-15	N/A
1/31/2015	N/A	-16	N/A	-13	N/A
10/31/2014	N/A	-14	N/A	-10	N/A
7/31/2014	N/A	-12	N/A	-9	N/A
4/30/2014	N/A	-10	N/A	-8	N/A
1/31/2014	N/A	-8	N/A	-7	N/A
10/31/2013	N/A	-7	N/A	-6	N/A
7/31/2013	N/A	-7	N/A	-6	N/A
4/30/2013	N/A	-7	N/A	-6	N/A
1/31/2013	N/A	-6	N/A	-5	N/A
10/31/2012	N/A	-7	N/A	-5	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista ONCS.Q è superiore al tasso di risparmio ( 2.1% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di ONCS.Q cresceranno più velocemente del mercato US

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di ONCS.Q cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di ONCS.Q cresceranno più rapidamente del mercato US.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di ONCS.Q cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di ONCS.Q è previsto essere elevato tra 3 anni

OncoSec Medical Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased to US$5.00

Price target decreased to US$5.00

Forecast to breakeven in 2024

Price target raised to US$8.13

Recent updates

OncoSec Medical Incorporated Announces Termination of George Chi as Chief Financial Officer

OncoSec Medical Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement

OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $1.330923 million.

Oncosec Medical Incorporated Announces Type C Meeting with the US Food and Drug Administration to Discuss Proposed Neoadjuvant Melanoma Clinical Program

High number of new directors

OncoSec Medical Incorporated Receives Notice from the Nasdaq Stock Market LLC

OncoSec Medical Incorporated has completed a Follow-on Equity Offering.

OncoSec Medical Incorporated has completed a Follow-on Equity Offering.

OncoSec Medical Incorporated Presents Encouraging Early Data with TAVO™-EP combined with Nivolumab (Opdivo®) in Neoadjuvant Melanoma

Oncosec Medical Incorporated Announces Positive Clinical Data of the Keynote-695 Trial Assessing Tavo-Ep in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to Anti-Pd-1 Treatment

OncoSec Medical Incorporated Elects Robert H. Arch as Non-Independent Director of the Board

OncoSec Medical Incorporated Elects Stephany Foster as an Independent Director

OncoSec Medical Incorporated Announces Workforce Reduction

OncoSec to cut workforce by 45% as part of corporate restructuring

OncoSec Medical Incorporated Appoints Joon Kim to the Audit Committee

OncoSec Medical Incorporated, Annual General Meeting, Nov 23, 2022

OncoSec Medical Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement

OncoSec Medical Incorporated Appoints Robert H. Arch as Chief Executive Officer

Price target decreased to US$5.00

Less than half of directors are independent

OncoSec Medical Incorporated, Annual General Meeting, Jul 12, 2022

Price target decreased to US$5.00

OncoSec Medical Incorporated Announces Appointment of George Chi as Chief Financial Officer

Oncosec Medical Receives Notice from the Nasdaq Stock Market

Less than half of directors are independent

Interim CEO & COO Brian Leuthner has left the company

Forecast to breakeven in 2024

President, CEO & Director Daniel O'Connor has left the company

OncoSec Medical Incorporated, Annual General Meeting, Apr 29, 2021

Price target raised to US$8.13

OncoSec Medical Incorporated Announces Publication in Clinical Cancer Research of Data Supporting the Therapeutic Potential of Lead Product Candidate, Tavo™, in Triple Negative Breast Cancer

OncoSec Medical Incorporated Appoints Bridget O'keeffe as Vice President of Clinical Development

OncoSec Medical Incorporated Announces Management Appointments

New 90-day high: US$7.71

OncoSec Announces First Subjects Dosed in Phase 1 Trial of Corvax12, Oncosec's Covid-19 Vaccine Candidate Combining Interleukin-12 (Il-12) with an Enhanced Sars-Cov-2 Spike Protein

What Type Of Shareholders Make Up OncoSec Medical Incorporated's (NASDAQ:ONCS) Share Registry?

OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $42.026498 million.

OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO™

New 90-day high: US$6.81

OncoSec Announces First Patient Dosed in Phase 2 Trial of TAVO™ Plus OPDIVO® as Neoadjuvant Therapy for Melanoma

Dosing underway in OncoSec's Tavo combo trial in skin cancer

New 90-day high: US$6.65

OncoSec Medical Incorporated Strengthens IP Portfolio with Allowance of Two European Patent Applications Covering TAVO and its Gene Electrotransfer Technology

OncoSec Medical Incorporated Announces Exclusive License Agreement for Cliniporator Gene Electrotransfer Platform Developed by IGEA Clinical Biophysics

OncoSec: Undervalued And Continuing To Make Progress

OncoSec Announces Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020

OncoSec drops 11% despite positive data from TAVO + Merck's Keytruda in metastatic melanoma

New 90-day high: US$5.11

OncoSec Medical Incorporated to Present Positive Interim Data from Keynote-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma

OncoSec Announces FDA Clearance of IND Application for Initiation of Phase 1 Clinical Trial of its CORVax12 Vaccine Candidate for COVID-19

OncoSec Medical Incorporated Announces Stepping Down of Kellie Malloy Foerter as Chief Operating Officer

OncoSec Medical Incorporated Announces Appointment of Sandra Aung as Senior Vice President, Chief Clinical Development Officer

OncoSec Announces Issuance of New U.S. Patent Expanding Coverage of TAVO and Its Gene Delivery Platform

OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $14.977914 million.

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita